
Mylan Recalls Alprazolam Tablets
The company is recalling Alprazolam Tablets, USP C-IV 0.5 mg because of potential presence of foreign substance.
Mylan Pharmaceuticals
While the company stated in a press release that it had not received any complaints of adverse events related to the recalled lot and that clinical impact from the foreign material would be rare, the risk of infection cannot be ruled out. Adverse events may be reported to FDA through the agency’s MedWatch program.
Source:
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.




